Diversified Trust Co Has $716,000 Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Diversified Trust Co decreased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 25.5% in the first quarter, HoldingsChannel reports. The firm owned 1,772 shares of the company’s stock after selling 606 shares during the period. Diversified Trust Co’s holdings in Medpace were worth $716,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Rise Advisors LLC purchased a new stake in Medpace during the first quarter valued at about $27,000. Mather Group LLC. acquired a new position in Medpace in the 1st quarter worth approximately $28,000. Contravisory Investment Management Inc. acquired a new position in Medpace in the 4th quarter worth approximately $26,000. RiverPark Advisors LLC purchased a new position in Medpace during the 4th quarter worth approximately $26,000. Finally, GAMMA Investing LLC purchased a new stake in shares of Medpace in the fourth quarter valued at $30,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP opened at $404.42 on Wednesday. The firm has a market cap of $12.53 billion, a PE ratio of 41.23, a PEG ratio of 2.04 and a beta of 1.36. Medpace Holdings, Inc. has a twelve month low of $227.21 and a twelve month high of $437.39. The firm’s 50 day moving average price is $397.69 and its 200 day moving average price is $369.55.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. The business had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. Medpace’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.27 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 11.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on MEDP shares. Guggenheim lifted their price target on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a report on Friday, June 7th. Robert W. Baird raised their price target on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Mizuho started coverage on shares of Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price for the company. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $443.14.

Insider Buying and Selling at Medpace

In other news, CEO August J. Troendle sold 15,102 shares of the stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the transaction, the chief executive officer now owns 791,541 shares of the company’s stock, valued at approximately $317,162,563.29. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO August J. Troendle sold 3,987 shares of Medpace stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $395.22, for a total value of $1,575,742.14. Following the transaction, the chief executive officer now owns 660,351 shares of the company’s stock, valued at $260,983,922.22. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the transaction, the chief executive officer now owns 791,541 shares in the company, valued at approximately $317,162,563.29. The disclosure for this sale can be found here. Insiders have sold a total of 29,621 shares of company stock worth $11,816,852 over the last three months. Corporate insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.